Iptacopan减少C3肾小球病患者的蛋白尿并稳定肾功能
该2期扩展研究纳入26例原生肾或移植后复发C3G成人患者,开放标签接受Iptacopan治疗。12个月时原生肾队列24小时UPCR显著降低57%,eGFR改善6.83 ml/min/1.73m2,血清C3升高;移植后复发队列蛋白尿和eGFR无显著变化,但血清C3显著升高。
要点
- 原生肾C3G患者接受Iptacopan 12个月,UPCR降低57%且eGFR改善。
- 移植后复发C3G患者肾功能稳定,血清C3显著升高。
- 肾活检C3沉积评分中位差值下降,提示组织学改善。
核心结论
- Iptacopan在原生肾C3G中显著降低蛋白尿并改善eGFR,在移植后复发C3G中稳定肾功能并升高血清C3。
研究设计与样本
- 2期开放标签扩展研究,纳入26例成人C3G患者,分为原生肾队列A和移植后复发队列B。
主要发现
- 队列A 12个月时24小时UPCR降低57%(P<0.0001,CI 0.31-0.59),eGFR改善6.83 ml/min/1.73m2(P=0.0174,CI 1.25-12.40)。
- 队列A血清C3几何均值比较基线比值为3.53(P<0.0001,CI 3.01-4.15)。
- 队列B 12个月时24小时UPCR降低21%(CI 0.48-1.31,P=0.3151),eGFR变化-0.96 ml/min/1.73m2(P=0.7335,CI -6.60至4.69)。
- 队列B血清C3比较基线比值为1.96(P<0.0001,CI 1.70-2.27)。
- 队列A+B肾活检C3沉积评分中位差值-7.00(CI -12.00至4.00)。
临床怎么用
- Iptacopan可能作为C3G的靶向治疗选择,尤其对原生肾患者可降低蛋白尿并改善肾功能。
- 移植后复发C3G患者使用Iptacopan可稳定肾功能并升高血清C3,但蛋白尿降低未达统计学显著。
局限性
- 本研究为开放标签、非对照的2期扩展研究,样本量小(26例),需进一步随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: C3 glomerulopathy (C3G) is a complex, chronic, ultra rare, progressive primary glomerulonephritis, resulting from alternative complement pathway overactivation, leading to kidney failure in most patients, and frequent recurrence in transplants. Iptacopan (LNP023) is an oral, proximal complement inhibitor specifically targeting factor B, that selectively inhibits the alternative complement pathway. METHODS: This was a phase 2 extension study of 26 adult patients with native kidney (cohort A), or recurrent C3G (post kidney transplantation; cohort B) receiving open label iptacopan. RESULTS: At 12 months, patients in cohort A had a significant reduction in 24-hour urine protein-to-creatinine ratio (UPCR; 57%; P < 0.0001; confidence interval [CI]: 0.31-0.59), an improvement in estimated glomerular filtration rate (eGFR; 6.83 ml/min per 1.73 m2; P = 0.0174; CI: 1.25-12.40), and an increase in serum C3 levels (geometric mean ratio to baseline: 3.53; P < 0.0001; CI: 3.01-4.15). In cohort B, most patients had normal urinary protein excretion at baseline (mean [range] 24-hour UPCR: 121 [9-445]), which was slightly lower by 12 months (21% reduction; CI: 0.48-1.31; P = 0.3151). In cohort B at 12 months, mean eGFR was at baseline values (mean change from baseline: -0.96 ml/min per 1.73 m2; P = 0.7335; CI: -6.60 to 4.69). Cohort B patients had significantly higher serum C3 values at 12 months compared with baseline (ratio:1.96; CI: 1.70-2.27; P < 0.0001). In cohorts A + B combined, the median difference in C3 deposit score on renal biopsy from baseline was -7.00 (CI: -12.00 to 4.00;) at 9 to 12 months treatment with iptacopan. CONCLUSION: These data provide a clinical rationale for further evaluation of long-term treatment of C3G with iptacopan.
引用
- Nester CM, Eisenberger U, Karras A, et al. Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy. Kidney Int Rep. 2024. PMID: 39990880. doi:10.1016/j.ekir.2024.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。